-transparent.png){kind=logo}
Four monoclonal antibodies to MH134 murine syngeneic hepatoma cells, 3H1, 7C2, 11G2, and 12A2, were produced by hybridomas constructed by fusing P3-X63-Ag8-U1 murine myeloma cells with spleen cells of a C3H/HeN mouse immunized with the syngeneic tumor cells. Immunodiffusion analysis with rabbit anti-mouse immunoglobulin antisera showed that 3H1, 7C2, 11G2, and 12A2 are IgG2a, IgM, IgG1, and IgG2a, respectively. Enzyme-linked immunosorbent assay using cells of five syngeneic tumor lines, MH134, MM102, MM46, MM48, and X5563, and lymph node cells of C3H/HeN and C57BL/6 mice showed that 3H1 specifically bound to MH134 tumor cells, whereas 7C2, 11G2, and 12A2 reacted not only with MH134 but also with MM102 and MM46 tumor cells. None of these monoclonal antibodies bound either to cells of MM48 or X5563 tumor lines or to normal lymph node cells. These results strongly suggest that MH134 tumor cells display at least two kinds of tumor-associated antigens on their cell surfaces: one is expressed uniquely by MH134 tumor cells, which are recognized by 3H1; the other is commonly shared by MH134, MM102, and MM46 tumor cells, which are determined by the other three antibodies. 3H1, 11G2, and 12A2 but not 7C2 were found to be able to induce antibody-dependent cellular cytotoxicity (ADCC) against MH134 tumor cells. Target specificity of ADCC induced by these monoclonal antibodies was identical with that seen in enzyme-linked immunosorbent assay. 3H1, 7C2, and 12A2 but not 11G2 exhibited complement-dependent cytotoxicity, showing the same specificity in target cell lysis as that seen in enzyme-linked immunosorbent assay or ADCC. Pretreatment of MH134 tumor cells with 7C2 inhibited ADCC of both 11G2 and 12A2. Pretreatment of the tumor cells with 11G2 inhibited complement-dependent cytotoxicity of both 7C2 and 12A2. Neither ADCC nor complement-dependent cytotoxicity of 3H1 was inhibited by the pretreatment of the cells with 7C2 or 11G2. These results strongly suggest that tumor-associated antigens recognized by 3H1 are located apart from that recognized by 7C2, 11G2, and 12A2 and that the binding sites of the latter three antibodies are closely associated with, or identical with, each other in the tumor-associated antigen. The ability of 12A2 to induce ADCC against MH134 tumor cells was significantly stronger than that of 3H1 or 11G2.(ABSTRACT TRUNCATED AT 400 WORDS)
I Kawase, and
K Komuta, and
T Ogura, and
H Fujiwara, and
T Hamaoka, and
S Kishimoto
September 1984,
Cancer research,
I Kawase, and
K Komuta, and
T Ogura, and
H Fujiwara, and
T Hamaoka, and
S Kishimoto
October 1976,
Gan,
I Kawase, and
K Komuta, and
T Ogura, and
H Fujiwara, and
T Hamaoka, and
S Kishimoto
January 1983,
Annals of the New York Academy of Sciences,
I Kawase, and
K Komuta, and
T Ogura, and
H Fujiwara, and
T Hamaoka, and
S Kishimoto
September 1980,
Journal of the Reticuloendothelial Society,
I Kawase, and
K Komuta, and
T Ogura, and
H Fujiwara, and
T Hamaoka, and
S Kishimoto
January 2012,
Oncoimmunology,
I Kawase, and
K Komuta, and
T Ogura, and
H Fujiwara, and
T Hamaoka, and
S Kishimoto
January 1985,
Japanese journal of cancer research : Gann,
I Kawase, and
K Komuta, and
T Ogura, and
H Fujiwara, and
T Hamaoka, and
S Kishimoto
January 1985,
The Journal of experimental medicine,
I Kawase, and
K Komuta, and
T Ogura, and
H Fujiwara, and
T Hamaoka, and
S Kishimoto
February 1998,
Journal of gastroenterology and hepatology,
I Kawase, and
K Komuta, and
T Ogura, and
H Fujiwara, and
T Hamaoka, and
S Kishimoto
January 1987,
Cancer immunology, immunotherapy : CII,
I Kawase, and
K Komuta, and
T Ogura, and
H Fujiwara, and
T Hamaoka, and
S Kishimoto
October 1984,
Journal of virology,
